ISSN: 1859 - 2872
Development of an in-house method for genotyping of ABCB1 3435C>T and its association with dose, concentration of tacrolimus in renal transplant patients
Main Article Content
Keywords
Abstract
Objective: To develop an in-house method for genotyping of ABCB1 genetic polymorphism and analyze its impact on the concentration and dose of tacrolimus in renal transplant patients. Subject and method: A total of 100 patients after kidney transplant were treated with tacrolimus at the Department of Nephrology and Dialysis - 103 Military Hospital, Military Medical University. Blood samples were collected to identify ABCB1 genetic polymorphisms of and monitor Tacrolimus levels. Primer design and restriction enzyme selection for setting up the genotyping of the polymorphism at 3435C>T (rs1045642). Analyzing the relationship between ABCB1 genotypes obtained with doses and concentrations of TAC at the time points of follow up. Result: In this study, a fragment 244bp containing ABCB1 3435C>T (rs1045642) genetic polymorphism was amplified by PCR. Enzyme MboI recognize the PCR product cutting sequence which generates 2 fragments of 172bp and 68bp, respectively, for the C allele or CC homozygous genotype. When the polymorphism is the T allele, the MboI enzyme cuts the PCR product to create a fragment with the corresponding size of 244bp or homozygous genotype TT. The CT heterozygous genotype corresponds to fragments with sizes of 244, 172, 68bp, respectively. There was no significant difference between ABCB1 3435C>T (rs1045642) genotypes and concentrations and doses of tacrolimus at different time points investigated. Conclusion: We have established a simple and reliable method for genotyping ABCB1 3435C>T (rs1045642). No effect of the polymorphism ABCB1 3435C>T (rs1045642) has been found in relation to the dose and concentration of tacrolimus in patients after kidney transplantation.
Article Details
References
2. Zawadzka I, Jeleń A, Pietrzak J, Żebrowska-Nawrocka M, Michalska K, Szmajda-Krygier D et al (2020) The impact of ABCB1 gene polymorphism and its expression on non-small-cell lung cancer development, progression and therapy - preliminary report. Sci Rep 10(1): 6188.
3. Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B et al (2013) Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene 512(2): 226-231.
4. Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, et al (2012) Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant Proc 44(1): 109-114.
5. Zhang X, Liu Z hong, Zheng J min, Chen Z hong, Tang Z, Chen J song, et al (2005) Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 19(5): 638-643.
6. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T (2005) Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 37(4): 1730-1732. doi: 10.1016/j.transproceed.2005.02.073.
7. Rong G, Jing L, Deng-Qing L, Hong-Shan Z, Shai-Hong Z, Xin-Min N (2010) Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Transplant Proc (9): 3455-3458.
8. Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O et al (2006) The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc 38(5): 1290-1292.
Article Sidebar
